CD57(high) neuroblastoma cells have aggressive attributes ex situ and an undifferentiated phenotype in patients.

Paired pre- and post-chemotherapy NB samples showed a trend to increased frequency of CD57 high cells in post-chemotherapy residual tumors in 7 out of 8 informative tumor pairs ( Fig. 8B, C and Table 1 ; two-tailed p = 0.11 using the paired-sample Wilcoxon signed rank test).

also in 53,322 other papers